Latest Financing News

Imugene Limited reports encouraging Phase 1b results for azer-cel in lymphoma, secures FDA Fast Track status, and strengthens patent portfolio while raising A$20 million to fuel ongoing immuno-oncology programs.

Australian Strategic Materials (ASM) has made significant strides in its mine to metals strategy during the March 2025 quarter, including plans for US expansion and progress at its Dubbo Project and Korean Metals Plant. The company is positioning itself as a key alternative supply chain amid escalating geopolitical tensions and export restrictions.

Tesoro Gold’s latest drilling at the El Zorro Project reveals significant high-grade gold beyond existing resource boundaries, while a fresh A$11.1 million capital raise sets the stage for accelerated development and exploration.

Native Mineral Resources Holdings Limited reported a $3.2 million net cash outflow from operations in Q1 2025 but strengthened its balance sheet with a $4.52 million capital raising post-quarter.

Lotus Resources is on track to restart uranium production at its Kayelekera project in Malawi by Q3 2025, backed by strong funding and binding offtake agreements covering up to 3.8 million pounds of uranium from 2026. Meanwhile, its Letlhakane project in Botswana advances with an updated scoping study supporting robust production potential.

Visionflex Group Limited reported a net cash outflow of AUD 1.34 million for Q1 2025, maintaining liquidity through convertible note facilities that extend funding runway to over two quarters.

MONEYME’s loan book surged to $1.5 billion in 3Q25, driven by a 65% jump in originations and steady revenue, underpinned by improved credit quality and innovative AI deployment.

Icon Energy Limited has received a Notice of Proposed Grant for Petroleum Lease PL-1144 in the Cooper Basin, marking a significant step toward resource development. Meanwhile, the company secured a $300,000 unsecured loan under revised terms, though its shares remain suspended pending native title negotiations and ASX approval.

Island Pharmaceuticals has completed dosing in the Phase 2b cohort of its dengue fever trial, with pharmacokinetic targets met and top-line results expected next month. The company also strengthened its balance sheet by raising $1.94 million through option exercises.

Top End Energy Limited reported a mixed quarterly cash flow with operating and investing outflows offset by robust financing inflows, ending March 2025 with over five quarters of funding available.

CurveBeam AI reported a robust 40% increase in purchase orders during Q3 FY25 and secured a non-binding A$18 million vendor financing term sheet, positioning the company for cashflow positivity in Q4.

Southern Palladium’s March quarter report highlights strong project economics from its Bengwenyama PGM project, with a $1.06 billion NPV and a mining right decision expected in Q2 2025. The company is progressing a Definitive Feasibility Study and project optimisation to accelerate production.